Therapy of acute and fulminant hepatitis B

Intervirology

Volumn 57, Issue 3-4, 2014, Pages 181-188

  Tillmann, Hans L ^a,b   Patel, Keyur ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Acute hepatitis; Antiviral therapy; Fulminant liver failure; Hepatitis B; Hepatitis B virus

Indexed keywords

ACETYLCYSTEINE; ADEFOVIR; ANTIVIRUS AGENT; BILIRUBIN; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; TELBIVUDINE; TENOFOVIR; ALPHA INTERFERON; GUANINE; HEPATITIS B VACCINE; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE; ANTIINFECTIVE AGENT; CLEVUDINE; VIRUS DNA;

ACUTE LIVER FAILURE; ANTIVIRAL THERAPY; ARTICLE; DELTA AGENT HEPATITIS; DISEASE SEVERITY; HEPATITIS B; HUMAN; JAUNDICE; LIVER TRANSPLANTATION; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; REINFECTION; RISK FACTOR; ANALOGS AND DERIVATIVES; BLOOD; HEPATITIS B VIRUS; IMMUNOLOGY; LIVER; LIVER FAILURE, ACUTE; PATHOLOGY; VIROLOGY; ACUTE HEPATITIS; ACUTE ON CHRONIC LIVER FAILURE; BILIRUBIN BLOOD LEVEL; CHRONIC HEPATITIS; CHRONICITY; CLINICAL FEATURE; DISEASE COURSE; EARLY INTERVENTION; HEPATITIS DELTA VIRUS; IMMUNE RESPONSE; IMMUNOCOMPETENCE; INFECTION RISK; INFLUENZA; MIXED INFECTION; MORTALITY; PAPULAR ACRODERMATITIS; POLYARTERITIS NODOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SEROCONVERSION; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS LOAD;

ANTIVIRAL AGENTS; GUANINE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; LIVER; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; THYMIDINE;

HEPATITIS B VIRUS;

EID: 84904646436     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000360939     Document Type: Article

References (63)

1. Komiya Y, Katayama K, Yugi H, Mizui M, Matsukura H, Tomoguri T, Miyakawa Y, Tabuchi A, Tanaka J, Yoshizawa H: Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 2008; 48: 286-294.
2. Hsia CC, Purcell RH, Farshid M, Lachenbruch PA, Yu MY: Quantification of hepatitis B virus genomes and infectivity in human serum samples. Transfusion 2006; 46: 1829- 1835.
3. Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y: e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 1976; 294: 746-749.
4. Liu MH, Sheng YJ, Liu JY, Hu HD, Zhang QF, Ren H: Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis. Ann Saudi Med 2013; 33: 169- 176.
5. CDC: Table 3.2: clinical characteristics of reported cases of acute, symptomatic hepatitis B - United States, 2011. www.cdc.gov/hepatitis/ Statistics/2011Surveillance/Table3.2.htm (accessed November 18, 2013).
6. Robert Koch Institute: https://www.rki.de/ DE/Content/Infekt/EpidBull/ Archiv/2012/ Ausgaben/38-12.pdf?-blob=publication (accessed November 18, 2013).
7. Mazzur S, Bastiaans MJ, Nath N: Hepatitis B virus (HBV) infection among children and adults in the Solomon Islands. Am J Epidemiol 1981; 113: 510-519.
8. Francis DP, Hadler SC, Thompson SE, Maynard JE, Ostrow DG, Altman N, Braff EH, O'Malley P, Hawkins D, Judson FN, Penley K, Nylund T, Christie G, Meyers F, Moore JN Jr, Gardner A, Doto IL, Miller JH, Reynolds GH, Murphy BL, Schable CA, Clark BT, Curran JW, Redeker AG: The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 1982; 97: 362-366.
9. Hovi L, Saarinen UM, Jalanko H, Pohjanpelto P, Siimes MA: Characteristics and outcome of acute infection with hepatitis B virus in children with cancer. Pediatr Infect Dis J 1991; 10: 809-812.
10. Walsh JH, Purcell RH, Morrow AG, Chanock RM, Schmidt PJ: Posttransfusion hepatitis after open-heart operations. Incidence after the administration of blood from commercial and volunteer donor populations. JAMA 1970; 211: 261-265.
11. Oliphant JW: Jaundice following Administration of human serum. Bull NY Acad Med 1944; 20: 429-445.
12. Mortimer PP: Arsphenamine jaundice and the recognition of instrument-borne virus infection. Genitourin Med 1995; 71: 109-119.
13. CDC: Table 11: clinical characteristics of patients with acute hepatitis by age group - United States, 2005. http://www.cdc.gov/mmwr/ preview/mmwrhtml/ss5603a1.htm#tab11.
14. Kim WR: Epidemiology of hepatitis B in the United States. Hepatology 2009; 49:S28-S34.
15. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM; US Acute Liver Failure Study Group: Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-954.
16. Chiaramonte M, Floreani A, Naccarato R: Hepatitis B virus infection in homes for the aged. J Med Virol 1982; 9: 247-255.
17. Hovi L, Saarinen UM, Jalanko H, Pohjanpelto P, Siimes MA: Characteristics and outcome of acute infection with hepatitis B virus in children with cancer. Pediatr Infect Dis J 1991; 10: 809-812.
18. John TJ, Ninan GT, Rajagopalan MS, John F, Flewett TH, Francis DP, Zuckerman AJ: Epidemic hepatitis B caused by commercial human immunoglobulin. Lancet 1979; 1: 1074.
19. Centers for Disease Control and Prevention (CDC): Notes from the field: deaths from acute hepatitis B virus infection associated with assisted blood glucose monitoring in an assisted-living facility - North Carolina, August- October 2010. MMWR Morb Mortal Wkly Rep 2011; 60: 182.
20. Zheteyeva YA, Tosh P, Patel PR, Martinez D, Kilborn C, Awosika-Olumo D, Khuwaja S, Ibrahim S, Ryder A, Tohme RA, Khudyakov Y, Thai H, Drobeniuc J, Heseltine G, Guh AY: Hepatitis B outbreak associated with a home health care agency serving multiple assisted living facilities in Texas, 2008-2010. Am J Infect Control 2014; 42: 77-81.
21. Dreesman JM, Baillot A, Hamschmidt L, Monazahian M, Wend UC, Gerlich WH: Outbreak of hepatitis B in a nursing home associated with capillary blood sampling. Epidemiol Infect 2006; 134: 1102-1113.
22. Lee WM, Stravitz RT, Larson, AM: Introduction to the revised American Association for the Study of Liver Diseases position paper on acute liver failure 2011. http://www.aasld.org/ practiceguidelines/Documents/AcuteLiver- FailureUpdate2011.pdf (accessed January 22, 2012).
23. Bernal W, Auzinger G, Dhawan A, Wendon J: Acute liver failure. Lancet 2010; 376: 190- 201.
24. Gerlich W, Stamm B, Thomssen R: Prognostische Bedeutung des quantitativen HBsAg- Nachweises bei der akuten Hepatitis B. Teilergebnisse einer kooperativen klinischen Studie des DFG-Schwerpunktes 'Virushepatitis'. Verh Dtsch Ges Inn Med 1977; 83: 554- 557.
25. Frosner GG, Schomerus H, Wiedmann KH, Zachoval R, Bayerl B, Backer U, Gathof GA, Sugg U: Diagnostic significance of quantitative determination of hepatitis B surface antigen in acute and chronic hepatitis B infection. Eur J Clin Microbiol 1982; 1: 52-58.
26. Chulanov VP, Shipulin GA, Schaefer S, Gerlich WH: Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses. J Med Virol 2003; 69: 313-323.
27. Michitaka K, Horiike N, Chen Y, Yatsuhashi H, Yano M, Kojima N, Ohkubo K, Tanaka Y, Yamamoto K, Ohno N, Onji M: Infectious source factors affecting the severity of sexually transmitted acute hepatitis due to hepatitis B virus genotype C. Intervirology 2005; 48: 112-119.
28. Oliphant JW: Jaundice following administration of human serum. Bull NY Acad Med 1944; 20: 429-445.
29. Sainokami S, Abe K, Sato A, Endo R, Takikawa Y, Suzuki K, Okamoto H: Initial load of hepatitis B virus (HBV), its changing profile, and precore/core promoter mutations correlate with the severity and outcome of acute HBV infection. J Gastroenterol 2007; 42: 241- 249.
30. Garfein RS, Bower WA, Loney CM, Hutin YJ, Xia GL, Jawanda J, Groom AV, Nainan OV, Murphy JS, Bell BP: Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatology 2004; 40: 865-873.
31. Lok AS, Ward JW, Perrillo RP, McMahon BJ, Liang TJ: Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med 2012; 156: 743-745.
32. Lok AS, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
33. European Association for the Study of the Liver: EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
34. Wiegand J, Wedemeyer H, Franke A, et al: Treatment of acute hepatitis B with lamivudine vs. placebo: a prospective randomized double-blinded multicenter trial. J Viral Hepat 2013, Epub ahead of print.
35. Kumar M, Satapathy S, Monga R, Das K, Hissar S, Pande C, Sharma BC, Sarin SK: A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45: 97-101.
36. Yu JW, Sun LJ, Zhao YH, Kang P, Li SC: The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci 2010; 55: 775-783.
37. Dao DY, Seremba E, Ajmera V, Sanders C, Hynan LS, Lee WM; Acute Liver Failure Study Group: Use of nucleoside (tide) analogues in patients with hepatitis B-related acute liver failure. Dig Dis Sci 2012; 57: 1349-1357.
38. Gerlich WH, Uy A, Lambrecht F, Thomssen R: Cutoff levels of immunoglobulin M antibody against viral core antigen for differentiation of acute, chronic, and past hepatitis B virus infections. J Clin Microbiol 1986; 24: 288- 293.
39. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A: Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-onchronic liver failure. Hepatology 2011; 53: 774-780.
40. Trepo C, Guillevin L: Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. J Autoimmun 2001; 16: 269-274.
41. Slusarczyk J, Michalak T, Nazarewicz-de Mezer T, Krawczyski K, Nowosawski A: Membranous glomerulopathy associated with hepatitis B core antigen immune complexes in children. Am J Pathol 1980; 98: 29-43.
42. Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, Cohen P; French Vasculitis Study Group: Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84: 313- 322.
43. Michitaka K, Horiike N, Chen Y, Duong TN, Konishi I, Mashiba T, Tokumoto Y, Hiasa Y, Tanaka Y, Mizokami M, Onji M: Gianotti- Crosti syndrome caused by acute hepatitis B virus genotype D infection. Intern Med 2004; 43: 696-699.
44. Tassopoulos NC, Koutelou MG, Polychronaki H, Paraloglou-Ioannides M, Hadziyannis SJ: Recombinant interferon-alpha therapy for acute hepatitis B: a randomized, doubleblind, placebo-controlled trial. J Viral Hepat 1997; 4: 387-394.
45. Tillmann HL, Hadem J, Leifeld L, et al: Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13: 256- 263.
46. Miyake Y, Iwasaki Y, Takaki A, Fujioka S, Takaguchi K, Ikeda H, Kobashi H, Sakaguchi K, Shiratori Y: Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med 2008; 47: 1293-1299.
47. Yu JW, Sun LJ, Yan BZ, Kang P, Zhao YH: Lamivudine treatment is associated with improved survival in fulminant hepatitis B. Liver Int 2011; 31: 499-506.
48. Mele A, Mariano A, Tosti ME, Stroffolini T, Pizzuti R, Gallo G, Ragni P, Zotti C, Lopalco P, Curtale F, Balocchini E, Spada E; SEIEVA Collaborating Group: Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign. Clin Infect Dis 2007; 44:e17-e24.
49. Buti M, Homs M, Rodriguez-Frias F, Funalleras G, Jardi R, Sauleda S, Tabernero D, Schaper M, Esteban R: Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat 2011; 18: 434-442.
50. Hughes SA, Wedemeyer H, Harrison PM: Hepatitis delta virus. Lancet 2011; 378: 73-85.
51. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakalolu Y, Deertekin H, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP; HIDIT Study Group: Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364: 322-331.
52. Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH: Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987; 92: 1844-1850.
53. Seeff LB, Beebe GW, Hoofnagle JH, Norman JE, Buskell-Bales Z, Waggoner JG, Kaplowitz N, Koff RS, Petrini JL Jr, Schiff ER, et al: A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med 1987; 316: 965-970.
54. Ozasa A, Tanaka Y, Orito E, et al: Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006; 44: 326-334.
55. Beasley RP, Hwang LY, Lin CC, Ko YC, Twu SJ: Incidence of hepatitis among students at a university in Taiwan. Am J Epidemiol 1983; 117: 213-222.
56. Kuruuzum Z, Ozgenc O, Havuk A, Cokuner A, Ari A, Celenkolu N: Rate of chronicity and time of disappearance of HBsAg following acute hepatitis B. Hepatogastroenterology 2009; 56: 466-469.
57. Moller B, Hopf U, Poschke S, Alexander M, Friedrich-Jahnicke B, Mostertz P, L'age M: Serological assessment of HBcAg and HBV DNA: its prognostic relevance in acute hepatitis B. Liver 1987; 7: 298-305.
58. Zhang HW, Yin JH, Li YT, Li CZ, Ren H, Gu CY, Wu HY, Liang XS, Zhang P, Zhao JF, Tan XJ, Lu W, Schaefer S, Cao GW: Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut 2008; 57: 1713-1720.
59. Redecker AG: Viral hepatitis: clinical aspects. Am J Med Sci 1975; 270: 9-16.
60. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, Maynard JE: Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151: 599-603.
61. Suzuki Y, Kobayashi M, Ikeda K, Suzuki F, Arfase Y, Akuta N, Hosaka T, Saitoh S, Kobayashi M, Someya T, Matsuda M, Sato J, Watabiki S, Miyakawa Y, Kumada H: Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol 2005; 76: 33-39.
62. Ito K, Yotsuyanagi H, Yatsuhashi H, et al: Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology 2014; 59: 89-97.
63. Lee HS, Byun JH, Kim CY: Etiology and outcome of acute viral hepatitis in Korean adults. J Korean Med Sci 1990; 5: 149-154.